dBTechno (Free subscription) | 20/11/2008
Washington (dbTechno) - Amgen Inc., a unit of Takeda Pharmaceutical Co. has been forced to suspend a late-stage trial of a very promising cancer drug. The experimental drug in question is known as motesanib and was going to be used in combination with other drugs as something that could treat lung cancer. The other drugs it was [...]
Market Watch (Free subscription) | 20/11/2008
TEL AVIV (MarketWatch) -- Amgen Inc., the Thousand Oaks, Calif., biotech major, and Takeda Pharmaceutical Co.'s Millennium subsidiary suspended enrollment of patients in a Phase III trial of motesanib combined with paclitaxel and carboplatin as a first-line treatment for advanced non-small-cell lung cancer. Early-mortality rates in the motesanib group were higher than those in the placebo...
Business Wire (Free subscription) | 04/11/2008
Research and Markets: A SWOT Framework Analysis of Amgen Inc. Completes This In-Depth 2008 Company AnalysisDUBLIN, Ireland--()--Research and Markets () has announced the addition of the "Analysis of Amgen Inc." company profile to their offering. A complete and comprehensive analysis of Amgen Inc., includes an overview of the industry the company operates in,...
Seattle Post-Intelligencer (Free subscription) | 07/11/2008
Amgen Inc., with more cash than all but two U.S. pharmaceutical industry rivals, is seeking to snatch up distressed biotechnology companies at bargain prices.
Market Watch (Free subscription) | 07/11/2008
SAN FRANCSICO (MarketWatch) -- Amgen Inc. said Friday it expects to have three more blockbuster drugs on the market over the next five years. A blockbuster drug is generally regarded as one that has $1 billion or more in annual sales. Amgen said it currently has five such drugs on the market. The biotech also said it expects results from 17 key Phase II and Phase III studies in...
Market Watch (Free subscription) | 07/11/2008
Amgen Inc. says it sees sales from two newer drugs offsetting an expected decline in sales for its top-selling product, the anemia-fighting therapy Aranesp.
Law Blog - WSJ.com (Free subscription) | 07/11/2008
Amgen Inc. said the financial fallout from safety concerns and reimbursement cuts for its flagship anemia drugs should bottom out during the first half of 2009, bolstering the company's position as it prepares for the anticipated approval and launch of a new drug for osteoporosis.
Market Wire - Pharmaceuticals and Biotech: Biotech (Free subscription) | 05/11/2008
... of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. are performing joint research focused on identifying and characterizing activators of cardiac myosin as back-up and follow-on potential drug candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics'...
Market Watch (Free subscription) | 23/10/2008
SAN FRANCISCO (MarketWatch) -- IBM Corp. on Thursday signed a five-year contract to provide information services to biotech giant Amgen Inc. . The deal is worth $500 million and could grow to $800 million if Amgen exercises three one-year contract extensions. IBM will provide Amgen with services such as electronic messaging systems, networks, helpdesk support and server-hosting...
San Fransisco Chronicle (Free subscription) | 22/10/2008
Biotech drugmaker Amgen Inc. says its profit leapt in the third quarter thanks to favorable comparison with a prior-year quarter weighed down by acquisition and restructuring charges. The company reports net income of $1.16 million, or $1.09 per share,...
Examiner (Free subscription) | 22/10/2008
Biotech drugmaker Amgen Inc. says its profit leapt in the third quarter thanks to favorable comparison with a prior-year quarter weighed down by acquisition and restructuring charges.
Seattle Times (Free subscription) | 22/10/2008
Biotech drugmaker Amgen Inc. says its profit leapt in the third quarter thanks to favorable comparison with a prior-year quarter weighed down by acquisition and restructuring charges.
Seeking Alpha China (Free subscription) | 23/10/2008
Amgen, Inc. (AMGN) Q3 FY08 Earnings Call Complete Story ยป
Market Watch (Free subscription) | 23/10/2008
BOSTON (MarketWatch) -- Amgen Inc. and Bristol-Myers Squibb lead drug stocks higher early Thursday, buoyed by both companies' positive third-quarter earnings reports. The Amex Pharmaceutical Index hopped 1.9% to 257.42 and the Amex Biotechnology Index edged up 0.9% to 643.92, outpacing the Dow Jones Industrial Average . Shares of Bristol-Myers jumped 3% to $18.01 as shares of Lilly leapt...
LA Times (Free subscription) | 23/10/2008
WASHINGTON -- Biotech drugmaker Amgen Inc. said Wednesday its profit leapt in the third quarter, thanks to a comparison with a prior-year quarter weighed down by acquisition and restructuring charges.
